Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
NervGen Pharma Corp. (NGEN) had Consolidated Net Income/Loss of $-31.64M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-31.64M |
|
-- |
|
-- |
|
$16.67M |
|
$-16.67M |
|
$-14.98M |
|
$-31.64M |
|
$-31.64M |
|
$-31.64M |
|
$-31.64M |
|
|
Consolidated Net Income/Loss |
$-31.64M |
$-31.64M |
|
$-16.67M |
|
$-16.63M |
|
72.33M |
|
72.33M |
|
$-0.44 |
|
$-0.44 |
|
| Balance Sheet Financials | |
$16.32M |
|
-- |
|
$0.29M |
|
$16.61M |
|
$12.39M |
|
-- |
|
-- |
|
$12.39M |
|
$4.22M |
|
$3.93M |
|
$4.22M |
|
79.65M |
|
| Cash Flow Statement Financials | |
$-13.96M |
|
$0.07M |
|
$17.01M |
|
$12.36M |
|
$15.80M |
|
$3.44M |
|
$2.58M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.32 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-13.96M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-749.87% |
|
-805.78% |
|
-190.50% |
|
-749.86% |
|
$0.05 |
|
$-0.19 |
|
$-0.19 |
|